PREVACID

Compare PREVACID  to:
Compare
Compare

Generic Name for PREVACID

Lansoprazole 15mg, 30mg; e-c delayed-release granules in caps.

Legal Classification:

Rx

Pharmacological Class for PREVACID

Proton pump inhibitor.

Manufacturer of PREVACID

Takeda Pharmaceuticals America, Inc.

Indications for PREVACID

Triple therapy (w. amoxicillin + clarithromycin) or dual therapy (w. amoxicillin; use only if allergic, intolerant, or resistant to clarithromycin) for H. pylori eradication in duodenal ulcer disease. Short-term treatment of active duodenal ulcer, active benign gastric ulcer, erosive esophagitis (EE), symptomatic GERD, and NSAID-associated gastric ulcers when NSAID use is continued. To reduce risk of NSAID-associated gastric ulcer in patients with history of gastric ulcer who need an NSAID. Maintenance of healing of duodenal ulcer, EE. Long-term treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome).

Adult dose for PREVACID

Take before eating. Do not crush or chew granules. Caps: swallow whole, or sprinkle granules and mix contents with food or juice (see literature) and take immediately. May open caps and mix granules in 40mL apple juice and give via NG tube; flush tube with more juice. SoluTabs: dissolve on tongue; swallow with or without water. May give via oral syringe or NG tube (see literature). Susp: mix in 30mL water and drink immediately; do not use NG tube. ≥18yrs: Triple therapy: lansoprazole 30mg + amoxicillin 1g + clarithromycin 500mg, all every 12 hours for 10 or 14 days. Dual therapy: lansoprazole 30mg + amoxicillin 1g, both every 8 hours for 14 days. Duodenal ulcer: 15mg once daily for 4 weeks. Gastric ulcer treatment: 30mg once daily for up to 8 weeks. EE treatment: 30mg once daily for up to 8 weeks; may repeat for 8 more weeks. If relapse occurs, may repeat 8-week course. GERD: 15mg once daily for up to 8 weeks. Maintenance of healing of duodenal ulcer or EE: 15mg once daily. Healing of NSAID-associated gastric ulcer: 30mg once daily for 8 weeks; NSAID ulcer risk reduction: 15mg once daily for up to 12 weeks. Hypersecretory conditions: Initially 60mg once daily, adjust as needed; give daily doses >120mg in divided doses.

Children's dosing for PREVACID

Take before eating. Do not crush or chew granules. Caps: swallow whole, or sprinkle granules and mix contents with food or juice (see literature) and take immediately. May open caps and mix granules in 40mL apple juice and give via NG tube; flush tube with more juice. SoluTabs: dissolve on tongue; swallow with or without water. May give via oral syringe or NG tube (see literature). Susp: mix in 30mL water and drink immediately; do not use NG tube. GERD or EE: ≤1 year: not recommended. 1–11 years: ≤30 kg: 15 mg once daily; >30 kg: 30 mg once daily. For both: give for up to 12 weeks; doses up to 30 mg twice daily have been used.

Also:

Warnings/Precautions for PREVACID

Severe hepatic impairment (consider dose reduction). Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions for PREVACID

May alter absorption of pH-dependent drugs (eg, ketoconazole, digoxin, iron, ampicillin). May antagonize atazanavir. Monitor theophylline, warfarin. Give at least 30 minutes before sucralfate. May give antacids concomitantly.

Adverse Reactions for PREVACID

Diarrhea, abdominal pain, nausea, constipation, headache.

Notes for PREVACID

See Amoxil entry for more information on amoxicillin. See Biaxin entry for more information on clarithromycin.

How is PREVACID supplied?

Caps 15mg—30, 1000
30mg—100, 1000
SoluTabs—30
Susp—30 packets/box

Related Disease:

Duodenal ulcers {DU}
Erosive esophagitis
GERD {GERD}
Hypersecretory conditions~Zollinger-Ellison syndrome
Ulcers, duodenal
Ulcers, gastric

Related Resources

Phase 2 study of TZP-102 for diabetic gastroparesis

June 29, 2010

Tranzyme Pharma announced positive results from its Phase 2 study of TZP-102 for the treatment of gastroparesis in patients with diabetes mellitus (DM).

NDA submitted for Xifaxan for treatment of non-constipation irritable bowel syndrome

June 08, 2010

Salix Pharmaceuticals announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of Xifaxan (rifaximin 550 mg tablets) for the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS) and IBS-related bloating.

FDA accepts NDA for Duexa for ulcer risk reduction in arthritis patients

May 26, 2010

Horizon Pharma announced that its New Drug Application (NDA) for Duexa was accepted by the FDA for the reduction of the risk of development of upper gastrointestinal ulcers in patients with arthritis and pain.

Proton pump inhibitors (PPIs) class labeling change to include fracture risk

May 26, 2010

The FDA has notified healthcare professionals and patients of labeling changes for prescription and over-the-counter (OTC) proton pump inhibitors (PPIs) to include new safety information about a possible increased risk of fractures with the use of these medications.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions